Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
81.1M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
40.9M
-
Shares change
-
+2.78M
-
Total reported value, excl. options
-
$1.19B
-
Value change
-
+$88.2M
-
Put/Call ratio
-
1.11
-
Number of buys
-
76
-
Number of sells
-
-39
-
Price
-
$29.21
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q4 2022
138 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share as of Q4 2022.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.9M shares
of 81.1M outstanding shares and own 50.42% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.76M shares), VR Adviser, LLC (2.7M shares), VANGUARD GROUP INC (2.11M shares), COMMODORE CAPITAL LP (2.02M shares), STATE STREET CORP (1.86M shares), Deep Track Capital, LP (1.77M shares), Paradigm Biocapital Advisors LP (1.75M shares), Vivo Capital, LLC (1.68M shares), Fairmount Funds Management LLC (1.37M shares), and BVF INC/IL (1.24M shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.